HealthyNCT03122067
Oxytocin's Effect on Social Pain Empathy
A study testing oxytocin treatment in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
Trial summary
The aim of the present experiment is to examine oxytocin's behavioral and neural effects on social pain empathy Read more about this study
- Who is it for?
- Ages 18 to 30 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- oxytocin treatment
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 10 Jan 2017to 30 Oct 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy participants without past or current psychiatric or neurological disorders
Who cannot join
- history of head injury
- medical or psychiatric illness
- smoking or drinking 24 hours before experiment
Trial locations and contacts
1 site in 1 country.
Keith Kendrick, Dr. contact
China1 site, 1 recruiting
- Recruiting
School of Life Science and Technology, University of Electronic Science and Technology of China
Chengdu, Sichuan, 611731
Benjamin Becker, Dr., ben_becker@gmx.de
About this study
Official title: Oxytocinergic Modulation of Perceived Social Exclusion
The aim of the present experiment is to examine oxytocin's behavioral and neural effects on social pain empathy
Read the detailed description
In the current study, the investigators plan to examine whether oxytocin modulates behavior and neural activity during observing another person being excluded in an online ball-tossing game (a modified cyberball paradigm).
- Conditions
- Healthy
- Being tested
- oxytocin treatment, placebo treatment
- Keywords
- oxytocin, social cognition, fMRI, empathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oxytocin treatmentDrug
intranasal administration of oxytocin
placebo treatmentDrug
intranasal administration of placebo
| Study group | Role | What they receive |
|---|---|---|
| oxytocin group | Experimental | male participants with oxytocin treatment Receives: Drug: oxytocin treatment |
| placebo group | Placebo comparator | male participants with placebo treatment Receives: Drug: placebo treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neural activity changes associated with oxytocin administration
fMRI-assessed brain activity during observing other being socially excluded
Measured: 45-60 minutes after drug administration
Secondary outcomes (1)
Behavioral changes associated with oxytocin administration: ball-tossing
Number of tosses to the other players (the excluder, new player, or previously excluded player)
Measured: 45-60 minutes after drug administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2017
- Study start10 Jan 2017
- Primary completion30 Oct 2018 (estimated)
- Study completion30 Oct 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Electronic Science and Technology of China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Keith Kendrick, University of Electronic Science and Technology of China
- Investigators
- Keith Kendrick, Dr., Principal investigator, School of Life Science and Technology, University of Electronic Science and Technology of China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03122067
- Sponsor's protocol ID
- UESTC-neuSCAN-33
- Status last verified
- Feb 2018
- First submitted
- 17 Apr 2017
- Last updated
- 7 Feb 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oxytocinergic Modulation of Perceived Social Exclusion
- ClinicalTrials.gov ID
- NCT03122067
- Acronym / sponsor ID
- UESTC-neuSCAN-33
- Conditions
- Healthy
- Keywords
- oxytocin, social cognition, fMRI, empathy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of Electronic Science and Technology of ChinaUniversity, hospital or other
- Study start
- 10 Jan 2017 (actual)
- Primary completion
- 30 Oct 2018 (estimated)
- Study completion
- 30 Oct 2018 (estimated)
- First posted
- 20 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present experiment is to examine oxytocin's behavioral and neural effects on social pain empathy
Detailed description
In the current study, the investigators plan to examine whether oxytocin modulates behavior and neural activity during observing another person being excluded in an online ball-tossing game (a modified cyberball paradigm).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| oxytocin group | Experimental | Drug: oxytocin treatmentmale participants with oxytocin treatment |
| placebo group | Placebo comparator | Drug: placebo treatmentmale participants with placebo treatment |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- healthy participants without past or current psychiatric or neurological disorders
Key exclusion criteria (3 listed)
- history of head injury
- medical or psychiatric illness
- smoking or drinking 24 hours before experiment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oxytocin treatmentintranasal administration of oxytocin | Drug | oxytocin group |
| placebo treatmentintranasal administration of placebo | Drug | placebo group |
Primary outcome
Neural activity changes associated with oxytocin administration
Time frame: 45-60 minutes after drug administration
fMRI-assessed brain activity during observing other being socially excluded
1 secondary outcome
Behavioral changes associated with oxytocin administration: ball-tossing
Time frame: 45-60 minutes after drug administration
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Feb 2018.
Related trials for Healthy
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
Not yet recruitingPhase 1
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Keith Kendrick, Dr. contact
Keith Kendrick, Dr. principal investigator
School of Life Science and Technology, University of Electronic Science and Technology of China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing oxytocin treatment in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Keith Kendrick, Dr. (k.kendrick.uestc@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neural activity changes associated with oxytocin administration (time frame: 45-60 minutes after drug administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2018; AzTrials last refreshed its copy on 1 Nov 2026.